identifi
potenti
antivir
btv
develop
optim
valid
three
assay
present
cpebas
assay
first
assay
develop
evalu
whether
compound
show
antivir
efficaci
use
screen
larg
compound
librari
meanwhil
cytotox
antivir
could
also
evalu
use
cpebas
assay
doserespons
assay
design
determin
rang
efficaci
select
antivir
ie
inhibitori
concentr
ic
effect
concentr
ec
well
rang
cytotox
cc
toa
assay
employ
initi
moa
studi
determin
underli
mechan
novel
antivir
btv
viral
lifecycl
possibl
effect
host
cellular
machineri
assay
vital
evalu
antivir
efficaci
cell
cultur
system
use
recent
research
lead
identif
number
novel
antivir
btv
btv
prototyp
doublestrand
rna
viru
genu
orbiviru
famili
reovirida
btv
one
import
diseas
domest
livestock
includ
sheep
goat
cattl
domest
anim
billionyear
loss
worldwid
exot
btv
serotyp
import
anim
pathogen
list
usda
high
consequ
livestock
pathogen
recent
reemerg
btv
caus
major
outbreak
diseas
cattl
sheep
sever
countri
across
northern
europ
result
econom
signific
model
system
btv
subject
extens
molecular
genet
structur
studi
sever
vaccin
develop
howev
due
lack
proper
assay
antivir
drug
discoveri
antivir
avail
btv
recent
high
throughput
screen
ht
campaign
use
btv
model
system
develop
optim
valid
cpebas
assay
identifi
potenti
broadspectrum
antivir
arbovirus
cpebas
assay
wellrecogn
assay
use
antivir
drug
discoveri
number
virus
induc
rapid
observ
cpeapoptosi
system
post
btv
infect
cpe
evid
vertebr
cell
includ
hela
bsr
hek
btvinduc
cpe
could
monitor
quantifi
use
variou
cell
viabil
detect
method
includ
celltit
glo
cell
viabil
reagent
kit
ctg
kit
kit
determin
number
viabl
cell
cultur
base
quantit
cellular
atp
present
signal
presenc
metabol
activ
live
cell
optim
condit
cpebas
assay
present
show
feasibl
mix
measur
one
step
protocol
flexibl
stabl
luminesc
signal
meanwhil
toxic
compound
reduc
cell
viabil
exclud
cpebas
assay
cpebas
assay
show
robust
reliabl
antivir
drug
discoveri
btv
use
screen
nih
molecular
librari
small
molecul
repositori
mlsmr
lead
identif
six
novel
cluster
potenti
antivir
lead
compound
potenti
antivir
compound
identifi
use
cpebas
assay
need
subject
tenconcentr
doserespons
assay
determin
rang
antivir
efficaci
cytotox
antivir
efficaci
repres
inhibitori
concentr
ic
effect
concentr
ec
concentr
drug
inhibit
virusinduc
cpe
halfway
baselin
maximum
cytotox
antivir
ie
cytotox
concentr
cc
concentr
drug
induc
cytotox
baselin
maximum
select
index
si
denot
si
si
calcul
cc
ic
determin
specif
antivir
virusinduc
cpe
ic
ec
cc
si
valu
critic
measur
determin
whether
antivir
compound
potent
select
drug
develop
antivir
show
overt
toxic
vitro
yet
prevent
viru
induc
cpe
product
viral
lifecycl
import
character
moa
initi
character
carri
toa
assay
determin
possibl
step
viral
lifecycl
affect
antivir
gener
antivir
compound
ad
cell
differ
time
preor
postviru
infect
antivir
ad
infect
cell
post
target
step
cours
infect
would
result
lower
activ
compar
one
ad
prior
step
thu
toa
studi
critic
determin
antivir
efficaci
compound
potenti
target
either
viral
lifecycl
host
machineri
involv
viral
lifecycl
three
assay
cell
viabil
determin
use
ctg
kit
follow
manufactur
instruct
detect
system
output
adequ
luminesc
signal
could
analyz
use
variou
inhous
softwar
assay
valid
perform
least
triplic
eight
replica
obtain
data
three
paramet
includ
mean
valu
ave
standard
deviat
stdev
coeffici
variat
cv
analyz
determin
robust
assay
robust
assay
determin
data
analyz
plot
use
variou
biostat
graphic
tool
maintain
bsr
cell
deriv
babi
hamster
kidney
bhk
cell
dulbecco
modifi
eagl
medium
dmem
contain
fetal
calf
serum
fc
penicillin
streptomycin
three
assay
plate
cell
dmem
fc
penicillin
streptomycin
optim
previous
medium
refer
assay
medium
three
assay
incub
cell
incub
co
humid
plaquepurifi
propag
type
btv
describ
previous
dilut
assay
medium
design
assay
dissolv
test
compound
dmso
form
stock
concentr
mm
store
stock
dilut
compound
desir
concentr
use
assay
medium
design
assay
seed
bsr
cell
micropl
black
format
x
via
microflo
select
dispens
seed
densiti
cellswel
seed
volum
antivir
efficaci
analysi
incub
cell
hr
till
cell
get
adher
plate
thoroughli
add
antivir
compound
final
concentr
well
mix
complet
dilut
btv
desir
titer
add
btv
denot
moi
well
control
well
add
assay
media
incub
infect
cell
hr
co
humid
hpi
thaw
equilibr
ctg
buffer
lyophil
ctg
substrat
room
temperatur
prior
use
reconstitut
homogen
ctg
reagent
solut
mix
lyophil
enzymesubstr
buffer
reagent
accord
manufactur
instruct
equilibr
assay
plate
room
temperatur
min
add
equal
volum
ctg
reagent
well
dispens
incub
min
room
temperatur
dark
measur
luminesc
signal
use
multimod
reader
integr
time
sec
seed
bsr
cell
micropl
black
format
x
via
dispens
seed
densiti
cellswel
seed
volum
antivir
efficaci
assay
cytotox
assay
respect
incub
cell
hr
co
humid
till
cell
well
attach
plate
process
assay
quarter
area
plate
compound
equival
plate
shown
tabl
measur
cell
viabil
use
ctg
kit
describ
protocol
step
column
add
assay
medium
dilut
compound
form
final
volum
treatment
incub
cell
co
humid
determin
cell
viabil
hpi
use
celltiterglo
kit
describ
previous
protocol
step
process
data
first
use
proper
inhous
softwar
base
luminesc
signal
obtain
via
multimod
reader
determin
mean
valu
averag
standard
deviat
stdev
treatment
well
coeffici
variat
cv
requir
valu
greater
transfer
process
data
softwar
biostat
graphic
softwar
tool
carri
nonlinear
regress
analysi
determin
valu
ec
cc
cellbas
cpe
assay
develop
optim
valid
vitro
use
luminescentbas
ctg
kit
identifi
novel
antivir
btv
describ
previous
tendos
respons
assay
employ
reflect
antivir
efficaci
cytotox
identifi
lead
compound
measur
number
metabol
viabl
cell
cultur
base
quantit
cellular
atp
present
live
cell
previou
report
number
potenti
antivir
compound
evalu
includ
compound
cluster
identifi
via
ht
btv
deriv
via
de
novo
synthesi
base
ec
cc
si
sever
promis
lead
compound
identifi
potent
antivir
efficaci
low
toxic
high
select
exampl
determin
ec
figur
si
determin
base
ec
cc
valu
nanomolar
scale
antivir
efficaci
low
toxic
consequ
high
si
indic
might
potent
select
antivir
btv
toa
assay
aim
determin
possibl
stage
viral
lifecycl
target
compound
ad
hr
prior
btv
infect
ie
hpi
antivir
efficaci
remain
nanomolar
scale
figur
indic
might
act
beyond
earli
stage
viral
lifecycl
viru
entri
furthermor
antivir
efficaci
remain
unchang
ad
infect
cell
later
hpi
ad
hpi
percentag
viabl
cell
decreas
treatment
cell
indic
less
protect
stage
viral
lifecycl
ad
hpi
protect
bsr
cell
btvinduc
cpe
sinc
first
cycl
btv
viral
replic
usual
complet
infect
cell
within
hpi
result
suggest
might
act
late
stage
btv
viral
lifecycl
viru
replic
packag
matur
egress
meanwhil
also
possibl
may
act
host
cellular
machineri
involv
late
viral
lifecycl
initi
identif
antivir
hit
one
key
step
antivir
drug
discoveri
develop
develop
robust
assay
includ
select
quantifi
marker
develop
simpl
protocol
obtain
suffici
signal
less
cv
biochem
cellbas
screen
design
provid
chemic
start
point
base
upon
robust
simpl
inexpens
assay
due
requir
reproduc
screen
process
potenti
larg
number
molecul
screen
cpebas
assay
design
meet
requir
identifi
effect
hit
larg
compound
librari
cpe
refer
advers
effect
cultur
cell
associ
multipl
virus
variou
assay
avail
use
cpe
indic
measur
varieti
differ
marker
indic
number
dead
cell
cytotox
number
live
cell
viabil
mechan
cell
death
apoptosi
commerci
reagent
cpebas
assay
avail
simpl
assay
protocol
exampl
ctg
kit
includ
singl
mix
measur
step
wide
use
quantifi
viru
induc
cpe
howev
cpebas
assay
limit
virus
could
induc
rapid
cpe
virus
induc
rapid
cpe
variou
assay
develop
exampl
repliconbas
assay
use
repliconharbor
cell
line
allow
screen
inhibitor
viral
replic
includ
translat
polyprotein
process
minusand
plusstrand
rna
synthesi
antisens
rna
strategi
virtual
screen
smallmolecul
librari
also
could
use
identifi
possibl
antivir
nevertheless
critic
efficaci
antivir
drug
valid
vitro
cellbas
assay
allow
evalu
antivir
efficaci
entir
viral
lifecycl
cpebas
assay
success
adapt
high
throughput
format
one
reliabl
robust
assay
screen
larg
compound
librari
includ
recent
accomplish
ht
screen
influenza
viru
sever
acut
respiratori
syndrom
coronaviru
sarscov
arenavirus
reoviru
bluetongu
viru
doserespons
assay
design
valid
antivir
efficaci
hit
identifi
via
singl
dose
cpebas
assay
usual
screen
larg
compound
librari
hit
although
identifi
antivir
activ
need
confirm
reveal
potenti
becom
drug
antivir
efficaci
compound
could
reveal
analysi
via
ec
cc
si
valu
use
dose
respons
analysi
meanwhil
offtarget
fals
posit
identifi
number
lead
compound
could
narrow
via
analysi
order
compound
potenc
toxic
could
rank
direct
futur
antivir
drug
discoveri
especi
structureact
relationship
sar
analysi
futur
medicin
chemistri
modif
fact
compound
deriv
compound
associ
good
druglik
properti
vitro
vivo
meet
requir
drug
must
determin
moa
ie
character
interact
compound
target
physiolog
concentr
variou
assay
develop
particular
antivir
ie
inhibit
target
accept
solubl
permeabl
protein
bind
select
metabol
toxic
profil
sinc
moa
studi
lowthroughput
assay
need
labori
effort
select
molecul
potent
ec
high
cc
high
si
valu
could
readili
analyz
understand
moa
compound
stage
add
depth
interpret
cellular
activ
absenc
toa
studi
design
narrow
stage
antivir
interact
viral
host
target
know
compound
competit
substrat
certain
stage
viral
lifecycl
could
provid
immedi
direct
moa
analysi
altern
potent
cell
base
assay
known
mechan
includ
assay
directli
screen
integras
inhibitor
inhibit
viru
bind
surfac
protein
could
use
provid
known
moa
actual
screen
hit
screen
may
wellrel
design
moa
actual
moa
may
also
need
subject
toa
mechan
action
studi
summari
use
three
assay
report
success
screen
identifi
sever
potent
antivir
btv
includ
particular
si
suggest
highli
select
btv
via
toa
moa
studi
present
origin
paper
propos
could
potenti
antivir
agent
interact
host
autophagi
machineri
could
develop
antibtv
drug
author
declar
compet
financi
interest
